De Facto will reposition Applied Cytometry as an independent, high performance software developer. To do this, it is developing an integrated PR campaign, including: media relations, search engine optimisation and online marketing. The agency will initially raise awareness of Applied Cytometry’s re-branding from ACS and its re-launched website. De Facto will subsequently harness key opinion leader comment as VenturiOne is adopted by leading research centres.
Commenting on the appointment of De Facto, Dr Tracey Long, Marketing Manager for Applied Cytometry, said, “With their in-depth experience in the clinical research and drug discovery sectors, De Facto was a natural choice.”
De Facto co-founder and Director, Kevin Payne, will lead the account.
END
Note to editors
De Facto Communications is part of the Bell Pottinger Group and one of Europe's most successful public relations consultancies in life science and healthcare. In partnership with our clients, we approach our work with a passion and commitment that delivers award-winning, integrated communications programmes based on effective strategy, original thinking and creativity. De Facto is headquartered in London and operates internationally with clients across Europe and the US. Further information on De Facto Communications can be found at www.defacto.com
